New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 10, 2014
16:12 EDTMDVN, MRKMedivation names Dawn Svoronos as Chief Commercial Officer
Medivation (MDVN) announced Dawn Svoronos has been appointed as its chief commercial officer, reporting to David Hung, M.D., founder, CEO and president of Medivation. Svoronos currently is a member of Medivation's Board of Directors and is a former president of Europe and Canada for Merck & Co. (MRK), where she oversaw commercial operations in approximately 30 EU and EU accession countries. Svoronos will lead Medivation's commercial organization on an interim basis and will participate in the company's search for a permanent chief commercial officer. Cheryl Cohen, Medivation's former chief commercial officer, has left the company to pursue other opportunities.
News For MDVN;MRK From The Last 14 Days
Check below for free stories on MDVN;MRK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 18, 2014
11:41 EDTMDVNCubist rises after report sparks takeover interest speculation
Subscribe for More Information
07:57 EDTMRKCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
August 13, 2014
18:02 EDTMRKMerck provides statement on role of PNEUMOVAX 23 in updated ACIP recommendations
Subscribe for More Information
16:52 EDTMRKMerck confirms FDA approval of BELSOMRA
Subscribe for More Information
15:30 EDTMRKFDA approves Belsomra sleep drug
The Food and Drug Administration approved Belsomra tablets for use as needed to treat difficulty in falling and staying asleep. Belsomra is an orexin receptor antagonist and is the first approved drug of this type. Belsomra will be dispensed with an FDA-approved patient Medication Guide that provides instructions for its use and important safety information. Belsomra is a controlled substance because it can be abused or lead to dependence. Belsomra is made by Merck, Sharpe & Dohme.
August 8, 2014
08:27 EDTMDVNMedivation price target raised to $105 from $100 at Brean Capital
Brean Capital raised its price target on Medivation to $105 from $100 following its Q2 report, citing raised guidance for Xtandi sales, royalties, and milestone payments and the potential for Xtandi to receive FDA approval in September to be used in the pre-chemo setting. Brean keeps it Buy rating on the stock.
07:33 EDTMDVNMedivation price target raised to $90 from $85 at UBS
Subscribe for More Information
August 7, 2014
18:41 EDTMDVNOn The Fly: After Hours Movers
Subscribe for More Information
16:39 EDTMDVNMedivation sees FY14 net sales of XTANDI $600M-$640M
Subscribe for More Information
16:37 EDTMDVNMedivation reports Q2 diluted EPS 60c, consensus 24c
Reports Q2 revenue $148.1M, consensus $125.62M.
16:07 EDTMDVNMedivation trading halted, pending news
Subscribe for More Information
15:33 EDTMDVN Notable companies reporting after market close
Subscribe for More Information
15:31 EDTMDVNNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include CBS (CBS), consensus 72c; Consolidated Edison (ED), consensus 54c; Monster Beverage (MNST), consensus 75c; News Corporation (NWSA), consensus 3c; NVIDIA (NVDA), consensus 20c; Computer Sciences (CSC), consensus 94c; CareFusion (CFN), consensus 72c;DeVry Education (DV), consensus 67c; Salix Pharmaceuticals (SLXP), consensus $1.72; Federal Realty (FRT), consensus $1.21; SolarCity (SCTY), consensus (99c); Medivation (MDVN), consensus 24c; Sprouts Farmers Market (SFM), consensus 18c; Alnylam Pharmaceuticals (ALNY), consensus (56c); Lions Gate (LGF), consensus 17c; Mercadolibre (MELI), consensus 56c; Post Holdings (POST), consensus 27c; Assured Guaranty (AGO), consensus 35c; Great Plains Energy (GXP), consensus 41c; Air Lease (AL), consensus 52c; Ubiquiti Networks (UBNT), consensus 51c; SemGroup (SEMG), consensus 35c.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use